Table 1:

Clinical characteristics of the study patients

	All Patients	Patients with New Carotid Infarcts	Patients with No New Carotid Infarct	P Value
Age^{^a}	64.9 ± 16.2	77.2 ± 11.9	64.3 ± 16.2	.14
Gender^{^a}	Male 117 (36%)	Male 1 (7.1%)	Male 116 (36.8%)	.02
	Female 212 (64%)	Female 13 (92.9%)	Female 199 (63.2%)
Race/Ethnicity	White 166 (50.5%)	White 7 (50%)	White 159 (50.5%)	.21
	Hispanic 33 (10%)		Hispanic 33 (10.5%)
	Asian 90 (27.4%)	Asian 4 (28.6%)	Asian 86 (27.3%)
	African American 30 (9.1%)	African American 3 (21.4%)	African American 27 (8.6%)
	Pacific Islander 1 (0.3%)		Pacific Islander 1 (0.3%)
	Unknown 9 (2.7%)		Unknown 9 (2.8%)
Smoking history	52 (15.8%)	4 (28.6%)	48 (15.2%)	.29
Diabetes	105 (31.9%)	5 (35.7%)	100 (31.7%)	.58
Hypertension^{^a}	233 (70.8%)	13 (92.9%)	220 (69.8%)	.10
Hyperlipidemia	186 (56.5%)	10 (71.4%)	176 (55.9%)	.26
ASA^{^a}	191 (58.1%)	11 (78.6%)	180 (57.1%)	.17
NSAIDs	78 (23.7%)	3 (21.4%)	75 (23.8%)	1.00
Anticoagulants	93 (28.3%)	5 (35.7%)	88 (27.9%)	.55
Antihypertensive Rx^{^a}	213 (64.7%)	13 (92.9%)	200 (63.5%)	.02
Diabetes Rx	59 (17.9%)	4 (28.6%)	55 (17.5%)	.29
Lipid-lowering Rx^{^a}	163 (49.5%)	10 (71.4%)	153 (48.6%)	.11
Time elapsed between baseline brain/carotid CT/CTA and follow-up imaging (days)	445.1 ± 442	390.2 ± 288	447.5 ± 447.7	.48
Follow-up imaging modality	CT 175 (53.2%), MRI 154 (46.8%)	CT 9 (64.3%), MRI 5 (35.7%)	CT 166 (52.7%), MRI 149 (47.3%)	.39

Note:—ASA indicates acetylsalicylic acid; NSAIDs, nonsteroidal anti-inflammatory drugs; Rx, treatment.
↵a Indicates variables that were different (P < .2) in the patients with new carotid infarcts and in the patients with no new carotid infarct and retained for the multivariate analysis.